In April, the Medicare Payment Advisory Committee (MedPAC) voted to recommend a change in the add-on payment for Part B drugs in their next report to Congress.
Currently, the add-on payment is the average sales price of the drug plus 6%. The new policy recommendations would alter payment to maintain the 6% add-on payment for low-cost drugs, reduce the add-on payment for mid- to higher-cost drugs, and place a cap on the add-on payment for the costliest drugs.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
The ACR sent a letter to MedPAC expressing concerns with these recommendations and highlighting the significant impacts these policies would have on rheumatologists. Of note, MedPAC recommendations are not binding; however, they do indicate future discussions on add-on payments.